We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

46 hedge funds and large institutions have $113M invested in MoonLake Immunotherapeutics in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

10% more funds holding

Funds holding: 42 → 46 (+4)

4.41% more ownership

Funds ownership: 89.42% → 93.83% (+4.4%)

3% more capital invested

Capital invested by funds: $109M → $113M (+$3.8M)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
46
Holders Change
+4
Holders Change %
+9.52%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
9
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$2.03M
2
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$711K
3
GCL
Glazer Capital LLC
New York
+$576K
4
PCM
Prelude Capital Management
New York
+$508K
5
Millennium Management
Millennium Management
New York
+$363K

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$1.52M
2
HM
HealthCor Management
New York
-$613K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$365K
4
SCM
Suvretta Capital Management
New York
-$361K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$106K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$10.5M – – –
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$7.81M -$365K -35,982 -5%
RI
3
RTW Investments
New York
$7.76M – – –
BlackRock
4
BlackRock
New York
$7.74M -$23.3K -2,290 -0.3%
RCM
5
RA Capital Management
Massachusetts
$7.25M – – –
Citadel Advisors
6
Citadel Advisors
Florida
$7.15M -$16.6K -1,636 -0.2%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$5.33M -$106K -10,429 -2%
GTC
8
Ghost Tree Capital
New York
$5.17M – – –
SCA
9
STALEY CAPITAL ADVISERS
Pennsylvania
$5.17M +$2.03M +200,000 +67%
CAM
10
Cormorant Asset Management
Massachusetts
$4.45M – – –
APM
11
Avidity Partners Management
Texas
$4.14M – – –
BC
12
Boxer Capital
California
$4.13M – – –
OCA
13
Octagon Capital Advisors
New York
$4.13M – – –
FC
14
Finepoint Capital
Massachusetts
$3.62M +$3.55M +350,000 New
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$3.31M – – –
ACM
16
Altium Capital Management
New York
$2.59M – – –
BCLSI
17
Bain Capital Life Sciences Investors
Massachusetts
$2.59M – – –
FCMV
18
Foresite Capital Management V
California
$2.59M – – –
TCM
19
Tekla Capital Management
Massachusetts
$2.58M – – –
EC
20
EcoR1 Capital
California
$2.07M – – –
RSCM
21
Rock Springs Capital Management
Maryland
$1.6M – – –
6CM
22
683 Capital Management
New York
$1.55M – – –
BCM
23
BlueCrest Capital Management
Jersey
$1.55M – – –
CCM
24
Consonance Capital Management
New York
$1.55M – – –
PMAM
25
Picton Mahoney Asset Management
Ontario, Canada
$725K +$711K +70,000 New
1
2

MLTX Hedge Fund Activity: Q2 2021 in Review

46 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2021, worth a combined $113M — up 3.5% from $109M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new MLTX positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $2.03M. The largest seller was Logos Global Management, cutting an estimated $1.52M.

  • 46 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2021, up from 42 in Q1 2021.
  • Funds reported $113M of MoonLake Immunotherapeutics stock for Q2 2021, up 3.5% quarter-over-quarter.
  • 6 funds opened new MoonLake Immunotherapeutics positions in Q2 2021 and 2 closed out, a net change of +4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2021 was STALEY CAPITAL ADVISERS, an estimated $2.03M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2021 was Logos Global Management, an estimated $1.52M sold.

Based on aggregated 13F filings for Q2 2021.